Catalyst
Slingshot members are tracking this event:
Kalvista(KALV) to present Phase 2 data of KVD900 in Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology (EAACI) Congress
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KALV | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 12, 2021
Occurred Source:
https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-presents-data-showing-single-demand
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Hereditary Angioedema, Kvd900
